IL2 and neoplasm: TIL-based ACT relies on (i) non-myeloablative lymphoid exhaustion, (ii) tumor-specific T cells isolated from tumor tissues, expanded in vitro, and injected into the host, and (iii) IL-2 administration after TIL infusion (100).